Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia

Clinical Infectious Diseases

Volumn 44, Issue 2, 2007, Pages 190-196

  Stryjewski, Martin E ^a,b,c   Szczech, Lynda A ^a   Benjamin Jr , Daniel K ^a   Inrig, Jula K ^a   Kanafani, Zeina A ^a   Engemann, John J ^a   Chu, Vivian H ^a   Joyce, Maria J ^a   Reller, L Barth ^a   Corey, G Ralph ^a   Fowler Jr , Vance G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b CEMIC   (Argentina)

^c NONE   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; VANCOMYCIN;

ADULT; APACHE; ARTICLE; BACTEREMIA; BLOOD CULTURE; COMORBIDITY; CONFIDENCE INTERVAL; DRUG TREATMENT FAILURE; DRUG USE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; LOADING DRUG DOSE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MULTIVARIATE ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS;

ADULT; AGED; BACTEREMIA; CEFAZOLIN; FEMALE; HUMANS; MALE; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; ODDS RATIO; RENAL DIALYSIS; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE; VANCOMYCIN;

EID: 33846140488     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/510386     Document Type: Article

References (34)

1. Marr KA, Sexton DJ, Conlon PJ, Corey GR, Schwab SJ, Kirkland KB. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med 1997; 127:275-80.
2. Quarles LD, Rutsky EA, Rostand SG. Staphylococcus aureus bacteremia in patients on chronic hemodialysis. Am J Kidney Dis 1985; 6:412-9.
3. Sexton DJ. Vascular access infections in patients undergoing dialysis with special emphasis on the role and treatment of Staphylococcus aureus. Infect Dis Clin North Am 2001; 15:731-42, vii.
4. Kessler M, Hoen B, Mayeux D, Hestin D, Fontenaille C. Bacteremia in patients on chronic hemodialysis: a multicenter prospective survey. Nephron 1993; 64:95-100.
5. Lentino JR, Baddour LM, Wray M, Wong ES, Yu VL. Staphylococcus aureus and other bacteremias in hemodialysis patients: antibiotic therapy and surgical removal of access site. Infection 2000; 28:355-60.
6. Berns JS. Infection with antimicrobial-resistant microorganisms in dialysis patients. Semin Dial 2003; 16:30-7.
7. Fogel MA, Nussbaum PB, Feintzeig ID, Hunt WA, Gavin JP, Kim RC. Cefazolin in chronic hemodialysis patients: a safe, effective alternative to vancomycin. Am J Kidney Dis 1998; 32:401-9.
8. Sowinski KM, Mueller BA, Grabe DW, et al. Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. Am J Kidney Dis 2001; 37:766-76.
9. Marx MA, Frye RF, Matzke GR, Golper TA. Cefazolin as empiric therapy in hemodialysis-related infections: efficacy and blood concentrations. Am J Kidney Dis 1998; 32:410-4.
10. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004; 48:4665-72.
11. Apellaniz G, Valdes M, Perez R, et al. Comparison of the effectiveness of various antibiotics in the treatment of methicillin-susceptible Staphylococcus aureus experimental infective endocarditis. J Chemother 1991; 3:91-7.
12. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34:1227-31.
13. Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003; 82:333-9.
14. Gonzalez C, Rubio M, Romero-Vivas J, Gonzalez M, Picazo JJ. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999;29:1171-7.
15. Gentry CA, Rodvold KA, Novak RM, Hershow RC, Naderer OJ. Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy 1997; 17:990-7.
16. Fortun J, Navas E, Martinez-Beltran J, et al. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin Infect Dis 2001; 33:120-5.
17. Rubio M, Romero J, Corral O, Roca V, Picazo JJ. Bacteremia by Staphylococcus aureus: analysis of 311 episodes [in Spanish]. Enferm Infecc Microbiol Clin 1999; 17:56-64.
18. Barth RH, DeVincenzo N. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int 1996; 50: 929-36.
19. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995;44(RR-12):1-13.
20. Marr KA, Kong L, Fowler VG, et al. Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients. Kidney Int 1998; 54:1684-9.
21. Engemann JJ, Friedman JY, Reed SD, et al. Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. Infect Control Hosp Epidemiol 2005; 26:534-9.
22. Reed SD, Friedman JY, Engemann JJ, et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2005; 26:175-83.
23. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-29.
24. Libman H, Arbeit RD. Complications associated with Staphylococcus aureus bacteremia. Arch Intern Med 1984; 144:541-5.
25. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 1994; 96:200-9.
26. Fowler VG Jr, Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003; 163: 2066-72.
27. NCCLS. Performance standards for antimicrobial susceptibility testing: twelfth informational supplement. M100-S12. Wayne, PA: NCCLS, 2002.
28. Fowler VG Jr, Justice A, Moore C, et al. Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40:695-703.
29. Fowler VG Jr, Kong LK, Corey GR, et al. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis 1999; 179:1157-61.
30. Hartstein AI, Mulligan ME, Morthland VH, Kwok RY. Recurrent Staphylococcus aureus bacteremia. J Clin Microbiol 1992; 30:670-4.
31. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38:1700-5.
32. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994; 18: 533-43.
33. Moellering RC Jr. Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin Infect Dis 1994; 18:544-6.
34. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother 1993; 27:594-8.